Literature DB >> 2893917

Natural history of localised prostatic cancer managed by conservative therapy alone.

N J George1.   

Abstract

The natural history of localised prostatic cancer was studied prospectively over 7 years. Within a single health district all patients with histologically confirmed cancer and negative 99mTc bone scans were managed, irrespective of clinical stage or pathological grade, according to a conservative regimen that included no form of anti-cancer treatment other than endoscopic resection for relief of urinary symptoms. Complete records were compiled on 120 of 152 patients (mean age 74.8 years, range 62-90) without metastases at diagnosis. Local tumour increased to palpable dimensions (T2/T3) in 100 of these patients (84%) but metastases developed in only 13, the mean time to scan conversion being 35.8 months. 23 patients were withdrawn from study and treated because of concern about increasing tumour size, and metastases developed in 1 of these. 5 patients died of prostatic cancer but the disease was not responsible for 48 additional deaths. Actuarial survival rates (excluding non-cancer deaths) at 5 and 7 years were 80% and 75%, respectively; the corresponding rate for those with metastases at presentation was 13% at 5 years. The likelihood that prostatic cancer will cause death within 7 years is indicated primarily by the scintigraphic findings at diagnosis.

Entities:  

Mesh:

Year:  1988        PMID: 2893917     DOI: 10.1016/s0140-6736(88)91294-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

Review 1.  Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2007-09       Impact factor: 3.092

Review 2.  Prostate cancer, screening, and prostate-specific antigen: promise or peril?

Authors:  J D Voss
Journal:  J Gen Intern Med       Date:  1994-08       Impact factor: 5.128

Review 3.  Prostate cancer: 2. Natural history.

Authors:  R K Nam; M A Jewett; M D Krahn
Journal:  CMAJ       Date:  1998-09-22       Impact factor: 8.262

Review 4.  Localised carcinoma of the prostate: a paradigm of uncertainty.

Authors:  S S Sandhu; A V Kaisary
Journal:  Postgrad Med J       Date:  1997-11       Impact factor: 2.401

5.  Attitude of African-Americans regarding prostate cancer clinical trials.

Authors:  S B Robinson; M Ashley; M A Haynes
Journal:  J Community Health       Date:  1996-04

6.  High dose intravenous oestrogen (fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate.

Authors:  M Ahmed; S Choksy; C P Chilton; K W Munson; J H Williams
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

7.  Dangers of long waiting times for outpatient appointments at a urology clinic.

Authors:  K German; F Nuwahid; P Matthews; T Stephenson
Journal:  BMJ       Date:  1993-02-13

8.  Screening for prostatic cancer.

Authors:  A K Nigam
Journal:  BMJ       Date:  1993-03-27

Review 9.  Active surveillance for prostate cancer: trials and tribulations.

Authors:  Laurence Klotz
Journal:  World J Urol       Date:  2008-09-24       Impact factor: 4.226

10.  Screening for prostate cancer. How can patients give informed consent?

Authors:  K G Marshall
Journal:  Can Fam Physician       Date:  1993-11       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.